Finally, within the report, we look to the future. Of course, we’ve already discussed some of the beta cell replacement therapy in the context of islet cell transplantation. But of course, because of the current limitations of donors for islet cell transplantation, there is a need to develop a more plenteous supply of beta cells. So we look at some of the latest bioengineering that’s being undertaken to develop beta cell replacement. And to think about ways that we can manipulate the immune system in order to reduce the need for anti-rejection therapies. But wouldn’t it be great to try to prevent type 1 diabetes in the future? And there are some very exciting trials at the moment of immunotherapies that are being used in the very early stages of type 1 diabetes to preserve beta cell function. And of course, this is a really exciting area that’s rapidly developing and we hope that perhaps next time when we update the report, we can include more information about how these therapies may be used in clinical practice. Ladies and gentlemen, I hope that today’s presentation will help you to support people with type 1 diabetes to live a long and healthy life. Thank you.